Skip to main content
ELAB
NASDAQ Life Sciences

NorthStrive Biosciences Expands AI Drug Discovery with Yuva, Targets Lead Nomination

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$5.23
Mkt Cap
$4.202M
52W Low
$5.06
52W High
$2,671.2
52W Position info
3.4% above low
Off High info
100% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ELAB is trading near its 52-week low of $5.06 (3.4% above the low) on light trading volume (0.1× avg).

Summary

NorthStrive Biosciences, a PMGC Holdings subsidiary, signed a First Amendment to its Development and License Agreement with Yuva Biosciences, launching a three-phase Expansion Program to advance four AI-discovered compounds toward lead nomination for cardiac disease and obesity. The program builds on positive Phase III results announced July 1, 2026, and is expected to take about six months. The amendment also strengthens the exclusive field of use and adds a right of first refusal across the broader cardiometabolic field. This is a meaningful step for a micro-cap company with a going concern warning, as it formalizes the next development stage and expands potential commercial rights. Watch for updates on Expansion Phase II confirmation results and the lead compound nomination expected from Phase III.

At the time of this announcement, ELAB was trading at $5.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $5.06 to $2,671.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ELAB - Latest Insights

ELAB
Nov 16, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $1.45 info
Change: -$0.1807 (-11%) info
Market Cap: $1.174M info
ELAB
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $1.45 info
Change: -$0.130 (-8%) info
Market Cap: $1.174M info
ELAB
Nov 02, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.12
Real-time Price: $1.45 info
Change: -$0.670 (-32%) info
Market Cap: $1.174M info
ELAB
Oct 01, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $3.62
Real-time Price: $1.45 info
Change: -$2.17 (-60%) info
Market Cap: $1.174M info
ELAB
Sep 18, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.70
Real-time Price: $1.45 info
Change: -$3.25 (-69%) info
Market Cap: $1.174M info